The $475,000 net proceeds provide minimal cash runway for a company with negative book value and a going concern warning. Monitor for additional capital needs — the company has already used $2.885M of its shelf capacity this year and may need further financing soon. The warrants at $1.00 are deeply out of the money relative to the $0.44 stock price, making near-term exercise unlikely.
Price Chart
Executive Summary
Mangoceuticals is conducting a dilutive registered direct offering of 657,000 shares of common stock and 657,000 common warrants at a combined price of $0.75 per unit, raising gross proceeds of $492,750 (net ~$475,000). The offering price represents a 70.5% premium to the last closing price of $0.44 on October 7, 2026. The warrants have a $1.00 exercise price and a 5-year term. The company's auditor has expressed substantial doubt about its ability to continue as a going concern. This is a small capital raise that provides minimal cash runway for a company with negative tangible book value.
Key Facts
- Offering of 657,000 shares + 657,000 warrants at $0.75/unit, gross proceeds $492,750
- Net proceeds estimated at ~$475,000 after ~$17,500 in expenses
- Warrant exercise price $1.00, exercisable immediately, 5-year term, with cashless exercise at 1.2x ratio
- Stock closed at $0.44 on Oct 7, 2026 — offering priced at 70.5% premium to market
- Pre-offering shares outstanding: 21,567,422; post-offering: 22,224,422 (3.0% dilution)
- Net tangible book value as of June 30, 2026 was negative $(1.12) million, or $(0.06) per share
- Post-offering as-adjusted net tangible book value remains negative at $(0.03) per share
- Auditor's report includes going concern qualification
- No placement agent or underwriter used; direct negotiation with investors
- Company has already sold $2,885,000 of securities under General Instruction I.B.6 in prior 12 months
Financial Impact
Gross proceeds of $492,750; net proceeds ~$475,000; 3.0% dilution to existing shareholders; immediate dilution of $0.78 per share for new investors
Risk Factors
- Going concern risk — auditor expressed substantial doubt about ability to continue
- Negative tangible book value of $(0.03) per share post-offering
- Minimal capital raise ($475K net) relative to cash needs
- Warrants at $1.00 are deeply out of the money (stock at $0.44), unlikely to provide additional capital
- Potential for further dilutive offerings given limited shelf capacity remaining
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-046508 |
| Document: 0001493152-26-046508-index-headers.html | 0001493152-26-046508 |
| Document: 0001493152-26-046508-index.html | 0001493152-26-046508 |
| Document: 0001493152-26-046508.txt | 0001493152-26-046508 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.3834 $0.2801 | ▲ +26.94% | ▲ +25.45% | $0.2440 (+36.36%) |
Oct 9, 2026 17d ago | 424B5 | $0.3834 $0.2801 | ▲ +26.94% | ▲ +25.45% | $0.2440 (+36.36%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4500 $0.3716 | ▼ −17.42% | ▼ −17.28% | $0.2440 (−45.78%) |
Oct 1, 2026 25d ago | 8-K | $0.4805 $0.4324 | ▼ −10.01% | ▼ −11.31% | $0.2440 (−49.22%) |
Jul 30, 2026 12w ago | 425 | $0.2936 $0.5270 | ▲ +79.50% | ▲ +75.87% | $0.2440 (−16.89%) |
Jul 30, 2026 12w ago | 8-K | $0.2936 $0.5270 | ▲ +79.50% | ▲ +75.87% | $0.2440 (−16.89%) |
Mar 6, 2026 33w ago | Press Release | $0.3470 $0.4040 | ▲ +16.43% | ▲ +17.78% | $0.2440 (−29.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers